<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02003911</url>
  </required_header>
  <id_info>
    <org_study_id>12-05-187</org_study_id>
    <nct_id>NCT02003911</nct_id>
  </id_info>
  <brief_title>Azithromycin for Children Hospitalized With Asthma</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Trial of Azithromycin in Children Hospitalized With Acute Asthma Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a chronic lung condition in children, and often requires hospitalization for acute&#xD;
      exacerbations. Azithromycin has been used successfully in other chronic lung diseases,&#xD;
      including cystic fibrosis. Despite limited clinical evidence, some pediatricians use&#xD;
      azithromycin in children hospitalized with asthma, citing either treatment of atypical&#xD;
      pathogens or its proposed anti-inflammatory properties. This study proposes a clinical trial&#xD;
      to determine if azithromycin will shorten length of stay in children hospitalized with acute&#xD;
      asthma exacerbations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is a chronic lung condition that accounts for over 130,000 pediatric hospitalizations&#xD;
      nationally at a cost of almost 1.4 billion dollars. Atypical pathogens have been implicated&#xD;
      both in initiating asthma and triggering acute asthma exacerbations. Azithromycin, a&#xD;
      macrolide antibiotic, is known to have antibacterial activity against atypical pathogens and&#xD;
      gram positive bacteria. More recently, macrolides have been increasingly used and effective&#xD;
      against gram negative bacteria and inflammation in the lungs of patients with chronic&#xD;
      respiratory illnesses. This effect may be secondary to the immunomodulatory effects&#xD;
      macrolides possess, in addition to their anti-bacterial effects. In long-term therapy with&#xD;
      macrolides, patients with asthma have shown improved bronchiolar hyperreactivity, spirometry,&#xD;
      symptoms, and quality of life. However, studies of short-term treatment in the acute setting&#xD;
      and in children are limited. Some practitioners use azithromycin in the treatment of acute&#xD;
      asthma, despite limited data.&#xD;
&#xD;
      The investigators propose a double-blind, randomized, placebo-controlled trial of&#xD;
      azithromycin in children aged 4-12 years with persistent asthma hospitalized with acute&#xD;
      asthma exacerbations. Children will be enrolled within 12 hours of admission and will be&#xD;
      randomized to receive three days of either azithromycin or placebo suspension (10mg/kg/dose,&#xD;
      max of 500mg). The primary outcome measure will be length of stay (LOS). Secondary outcome&#xD;
      measures will include: days of school/work missed, readmission rates, return to medical care&#xD;
      rates, recurrence of symptoms, and steroid courses. In the future, patients may also be&#xD;
      approached to enroll in the &quot;Mechanism Subset Study&quot; a separate pilot and feasibility study&#xD;
      which will require two blood samples and two nasal aspirate samples and will test for&#xD;
      atypical pathogens, interleukin-8 levels, and neutrophil/eosinophil counts. The average&#xD;
      length of stay for patients in this age range with asthma in 2011 at our institution was 3.0&#xD;
      days. The investigators will enroll to achieve a power of 80%, with an alpha of 0.05, which&#xD;
      will require 107 patients in each group to detect a 16 hour (0.67 day) difference in the&#xD;
      primary outcome, LOS. This study hypothesizes that azithromycin treatment in children&#xD;
      hospitalized with acute asthma will decrease LOS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Admission time to discharge time (average LOS is 3 days)</time_frame>
    <description>Hospital length of stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Readmission Rate</measure>
    <time_frame>One month after discharge</time_frame>
    <description>Number of hospital readmissions for asthma at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>School Missed</measure>
    <time_frame>One month after discharge</time_frame>
    <description>Days of school missed by patient at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Missed</measure>
    <time_frame>One month after discharge</time_frame>
    <description>Days of work missed by parent/guardian at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Room Visits</measure>
    <time_frame>One month after discharge</time_frame>
    <description>Number of emergency room visits for asthma symptoms since discharge at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Office Visits</measure>
    <time_frame>One month after discharge</time_frame>
    <description>Number of physician office visits for asthma symptoms since discharge at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of Asthma Symptoms</measure>
    <time_frame>One month after discharge</time_frame>
    <description>Number of recurrences of asthma symptoms since discharge at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid Courses</measure>
    <time_frame>One month after discharge</time_frame>
    <description>Number of courses of oral steroids since discharge at telephone follow-up phone call 1-month after discharge</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Routine Clinical Results and Symptoms</measure>
    <time_frame>One week after discharge</time_frame>
    <description>Respiratory viral panel or rapid viral testing results (if obtained as part of medical care), chest x-ray results/lab results (if obtained as part of medical care), vital signs, medications received during admission, medication side effects (diarrhea, abdominal pain, vomiting, flatulence), transfer to intensive care unit, time of wean of beta-agonists (q3h and q4h), and asthma severity (PASS score) at time of enrollment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Azithromycin suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo suspension</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same volume as active drug&#xD;
Once daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin suspension (200mg/5mL)</description>
    <arm_group_label>Azithromycin suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  4-12 years of age&#xD;
&#xD;
          -  Admission diagnosis of asthma at the Children's Hospital at Montefiore&#xD;
&#xD;
          -  History of persistent asthma (as defined by National Heart, Lung, and Blood Institute)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent bacterial infection requiring antibiotics&#xD;
&#xD;
          -  Antibiotics received within previous 2 weeks&#xD;
&#xD;
          -  Contraindication to azithromycin (including allergy to macrolides)&#xD;
&#xD;
          -  Chronic lung disease other than asthma (including bronchopulmonary dysplasia, cystic&#xD;
             fibrosis, bronchiectasis) or home oxygen requirement&#xD;
&#xD;
          -  Immunodeficiency (primary or acquired)&#xD;
&#xD;
          -  Chronic systemic steroid use&#xD;
&#xD;
          -  Invasive or non-invasive mechanical ventilation required acutely as result of current&#xD;
             asthma admission&#xD;
&#xD;
          -  Significant cardiac co-morbidity (including hemodynamically significant cardiac&#xD;
             disease or arrhythmia)&#xD;
&#xD;
          -  Liver disease (hepatitis)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Seizure disorder, currently on anti-epileptic medication)&#xD;
&#xD;
          -  Receiving albuterol every 4 hours (q4h) at the time of enrollment&#xD;
&#xD;
          -  Previous enrollment in study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey C Douglas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katherine O'Connor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diana S. Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alyssa H Silver, MD</last_name>
    <role>Study Director</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <results_first_submitted>February 25, 2020</results_first_submitted>
  <results_first_submitted_qc>August 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2020</results_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Acute asthma exacerbation</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Macrolide</keyword>
  <keyword>Length of Stay</keyword>
  <keyword>Hospital Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 4, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02003911/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azithromycin Suspension</title>
          <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days&#xD;
Azithromycin: Azithromycin suspension (200mg/5mL)</description>
        </group>
        <group group_id="P2">
          <title>Placebo Suspension</title>
          <description>Same volume as active drug&#xD;
Once daily for 3 days&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azithromycin Suspension</title>
          <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days&#xD;
Azithromycin: Azithromycin suspension (200mg/5mL)</description>
        </group>
        <group group_id="B2">
          <title>Placebo Suspension</title>
          <description>Same volume as active drug&#xD;
Once daily for 3 days&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" lower_limit="5.3" upper_limit="9.4"/>
                    <measurement group_id="B2" value="7.1" lower_limit="5.2" upper_limit="9.4"/>
                    <measurement group_id="B3" value="7.3" lower_limit="5.2" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PASS Score on enrollment</title>
          <description>PASS=Pediatric Asthma Severity Score&#xD;
Range 0 (best) - 6 (worst)&#xD;
Score at each time point is calculated by adding 3 elements:&#xD;
Wheeze (0= None/Mild, 1=Moderate, 2=Severe) Prolonged expiration (0= None/Mild, 1=Moderate, 2=Severe) Work of breathing (0= None/Mild, 1=Moderate, 2=Severe)</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.35" spread="1.25"/>
                    <measurement group_id="B2" value="2.71" spread="1.29"/>
                    <measurement group_id="B3" value="2.53" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Stay</title>
        <description>Hospital length of stay</description>
        <time_frame>Admission time to discharge time (average LOS is 3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin Suspension</title>
            <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days&#xD;
Azithromycin: Azithromycin suspension (200mg/5mL)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suspension</title>
            <description>Same volume as active drug&#xD;
Once daily for 3 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <description>Hospital length of stay</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.33" upper_limit="2.48"/>
                    <measurement group_id="O2" value="1.86" lower_limit="1.33" upper_limit="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Readmission Rate</title>
        <description>Number of hospital readmissions for asthma at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
        <time_frame>One month after discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin Suspension</title>
            <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days&#xD;
Azithromycin: Azithromycin suspension (200mg/5mL)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suspension</title>
            <description>Same volume as active drug&#xD;
Once daily for 3 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Readmission Rate</title>
          <description>Number of hospital readmissions for asthma at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>School Missed</title>
        <description>Days of school missed by patient at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
        <time_frame>One month after discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin Suspension</title>
            <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days&#xD;
Azithromycin: Azithromycin suspension (200mg/5mL)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suspension</title>
            <description>Same volume as active drug&#xD;
Once daily for 3 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>School Missed</title>
          <description>Days of school missed by patient at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Missed</title>
        <description>Days of work missed by parent/guardian at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
        <time_frame>One month after discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin Suspension</title>
            <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days&#xD;
Azithromycin: Azithromycin suspension (200mg/5mL)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suspension</title>
            <description>Same volume as active drug&#xD;
Once daily for 3 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Work Missed</title>
          <description>Days of work missed by parent/guardian at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergency Room Visits</title>
        <description>Number of emergency room visits for asthma symptoms since discharge at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
        <time_frame>One month after discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin Suspension</title>
            <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days&#xD;
Azithromycin: Azithromycin suspension (200mg/5mL)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suspension</title>
            <description>Same volume as active drug&#xD;
Once daily for 3 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Emergency Room Visits</title>
          <description>Number of emergency room visits for asthma symptoms since discharge at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Office Visits</title>
        <description>Number of physician office visits for asthma symptoms since discharge at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
        <time_frame>One month after discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin Suspension</title>
            <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days&#xD;
Azithromycin: Azithromycin suspension (200mg/5mL)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suspension</title>
            <description>Same volume as active drug&#xD;
Once daily for 3 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Office Visits</title>
          <description>Number of physician office visits for asthma symptoms since discharge at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence of Asthma Symptoms</title>
        <description>Number of recurrences of asthma symptoms since discharge at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
        <time_frame>One month after discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin Suspension</title>
            <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days&#xD;
Azithromycin: Azithromycin suspension (200mg/5mL)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suspension</title>
            <description>Same volume as active drug&#xD;
Once daily for 3 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence of Asthma Symptoms</title>
          <description>Number of recurrences of asthma symptoms since discharge at telephone follow-up phone calls at 1-week and 1-month interval after discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steroid Courses</title>
        <description>Number of courses of oral steroids since discharge at telephone follow-up phone call 1-month after discharge</description>
        <time_frame>One month after discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin Suspension</title>
            <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days&#xD;
Azithromycin: Azithromycin suspension (200mg/5mL)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Suspension</title>
            <description>Same volume as active drug&#xD;
Once daily for 3 days&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Steroid Courses</title>
          <description>Number of courses of oral steroids since discharge at telephone follow-up phone call 1-month after discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Routine Clinical Results and Symptoms</title>
        <description>Respiratory viral panel or rapid viral testing results (if obtained as part of medical care), chest x-ray results/lab results (if obtained as part of medical care), vital signs, medications received during admission, medication side effects (diarrhea, abdominal pain, vomiting, flatulence), transfer to intensive care unit, time of wean of beta-agonists (q3h and q4h), and asthma severity (PASS score) at time of enrollment.</description>
        <time_frame>One week after discharge</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Azithromycin Suspension</title>
          <description>Azithromycin suspension at 10mg/kg/dose (max 500mg)&#xD;
Once daily for 3 days&#xD;
Azithromycin: Azithromycin suspension (200mg/5mL)</description>
        </group>
        <group group_id="E2">
          <title>Placebo Suspension</title>
          <description>Same volume as active drug&#xD;
Once daily for 3 days&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Transfer to PICU</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Study Exit</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination and power of findings&#xD;
Urban population may not be generalizable&#xD;
High asthma severity of participants&#xD;
Systemic steroids given during hospitalization&#xD;
Antimicrobial role of azithromycin (Mechanism not studied)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Lindsey Douglas</name_or_title>
      <organization>Mount Sinai Kravis Children's Hospital</organization>
      <phone>2122416500</phone>
      <email>lindsey.douglas@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

